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OBJECTIVES This study examined the effect of aspirin on the risk of embolic events in infective
endocarditis (IE).
BACKGROUND Embolism is a major complication of IE, and studies in animal models have shown that
platelet inhibition with aspirin can lead to more rapid vegetation resolution and a lower rate
of embolic events.
METHODS We conducted a randomized, double-blinded, placebo-controlled trial of aspirin treatment
(325 mg/day) for four weeks in patients with IE to test the hypothesis that the addition of
aspirin would reduce the incidence of clinical systemic embolic events. Patients with
perivalvular abscess were excluded. Serial cerebral computed tomograms and transesophageal
echocardiograms were obtained in a subset of patients.
RESULTS During the four-year study period, 115 patients were enrolled: 60 assigned to aspirin and 55
assigned to placebo. Embolic events occurred in 17 patients (28.3%) on aspirin and 11
patients (20.0%) on placebo, with an odds ratio (OR) of 1.62 (95% confidence interval [CI]
0.68 to 3.86, p  0.29). There was a trend toward a higher incidence of bleeding in the
patients taking aspirin versus placebo (OR 1.92, 95% CI 0.76 to 4.86, p  0.075).
Development of new intracranial lesions was similar in both groups. Aspirin had no effect on
vegetation resolution and valvular dysfunction.
CONCLUSIONS In endocarditis patients already receiving antibiotic treatment, the addition of aspirin does not
appear to reduce the risk of embolic events and is likely associated with an increased risk of
bleeding. Aspirin is not indicated in the early management of patients with IE. (J Am Coll
Cardiol 2003;42:775–80) © 2003 by the American College of Cardiology Foundation
Infective endocarditis (IE) is a serious medical condition
that carries high mortality and morbidity (1–3). Although
many patients respond favorably to medical treatment, the
course of the disease may be complicated by valvular
destruction, abscess formation, embolism, and heart failure.
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Embolism occurring in approximately one-third of these
patients remains a major complication and is one of the
main causes of death (4–7). In patients already receiving
antibiotic treatment, there is no proven effective medical
therapy to reduce the risk of embolism (8–11).
Platelets are an integral component of the vegetation that
is a hallmark of endocarditis (12–14). Recent studies in
animal models suggest that aspirin may lead to more rapid
resolution of vegetation, thus reducing the embolic rate
(14,15). A favorable effect of aspirin on clinical outcome was
also suggested by a small observational study (16). The
objective of the present study was to determine the effect of
aspirin on the frequency of embolic events in patients who
had native or prosthetic valve endocarditis but no evidence
of perivalvular abscess.
METHODS
This was a double-blinded, placebo-controlled, randomized
trial in which 18 Canadian centers and one American center
participated. The patients were enrolled between July 1994
and June 1998. The investigators at each site included at
least one cardiologist and one infectious disease specialist.
The cardiologist screened the echocardiographic findings of
patients referred for suspected endocarditis on a daily basis
and reviewed the clinical records, as appropriate, to deter-
mine whether the patients had endocarditis according to
predefined criteria (as described in the following text).
Similarly, all patients with positive blood cultures were
reviewed, and further investigations, including echocardiog-
raphy, were recommended, as appropriate. This systematic
approach was to ensure that potential patients were identi-
fied early and the diagnosis promptly made.
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Inclusion and exclusion criteria. Patients were eligible to
participate in the study if they fulfilled the diagnostic criteria
of endocarditis, which were similar but not identical to the
Duke criteria (17). The diagnosis of endocarditis required
the presence of two of the following three criteria: 1)
multiple positive blood cultures (at least two sets) with no
known extracardiac source; 2) echocardiographic evidence
of vegetation, defined as a localized, mobile mass contiguous
with a valve leaflet or prosthetic valve; and 3) at least two of
the following clinical findings: fever, new or changing heart
murmur, pre-existing heart disease, and microvascular phe-
nomena. Patients between 16 and 80 years of age with
native valve or prosthetic valve endocarditis were eligible.
Exclusion criteria included patients with isolated right-sided
endocarditis, echocardiographic evidence of perivalvular ab-
scess (defined as an abnormal echolucent mass within the
perivalvular tissue), probable surgical intervention within 7
days, current use of aspirin, recent or actively evolving
stroke, history of gastrointestinal bleeding or active peptic
ulcer disease within the past 12 months, history of a
bleeding diathesis, allergic or intolerance to aspirin, and
inability or unwillingness to provide informed consent.
Randomization procedure. Computer-generated, strati-
fied (i.e., native vs. prosthetic valve and study center)
randomization was completed using the SAS RANNOR
module (SAS Institute Inc., Cary, North Carolina). The
randomization ratio was in a 1:1 allocation, with a small
block size. Adequate allocation concealment was achieved
through opaque, sealed, sequentially numbered envelopes
containing participant assignment at each recruitment site.
This study was reviewed and approved by the research
ethics committee of all of the participating centers, and
written, informed consent was obtained from all patients.
Blinding. The treating physicians as well as investigators
were blinded to patient assignment. Aspirin and placebo
tablets were identical in appearance. They were manufac-
tured and donated by Merck Frosst Canada and Company
(Kirkland, Quebec). The investigators could request un-
blinding (if knowledge of drug assignment was believed to
be important to patient management) by telephoning the
coordinating center at a specified phone number that was
manned 24 h/day. During the conduct of the study, there
were two instances of unblinding. Both occurred in patients
who developed intracranial hemorrhage and were being
evaluated for surgical drainage of the hematoma.
Intervention and outcomes. Eligible patients were ran-
domized to receive either aspirin (325 mg/day) or placebo
for a total duration of four weeks to test the hypothesis that
aspirin can reduce the risk of embolism in patients with
endocarditis by enhancing vegetation resolution (14,15). In
patients with mechanical prosthetic valves, anticoagulation
therapy was continued (18). The patients were seen at least
twice weekly throughout their entire hospitalization. In the
setting of early discharge with home intravenous antibiotic
therapy, the patients were brought back for follow-up at the
completion of antibiotic therapy. At each visit, a history was
taken and physical examination performed to specifically
look for evidence of thromboembolic events. Predefined
criteria for cerebrovascular and peripheral embolism were
used (see subsequent text). In patients with a suspected
neurologic event, an assessment by a neurologist was re-
quested, and a computed tomogram of the brain was
performed when clinically indicated. All patients were
encouraged but not required to have a baseline cerebral
computed tomogram and a follow-up study at the comple-
tion of antibiotic therapy, usually four to six weeks after the
baseline study. Transthoracic echocardiograms were ob-
tained in all patients at baseline and again at the completion
of antibiotic therapy. Transesophageal echocardiographic
studies were encouraged but, again, not required for partic-
ipation in the study. The maximum widths, lengths, and
areas of the vegetations were measured off-line (19), and the
valvular regurgitation was graded from 0 (no regurgitation)
to 4 (severe regurgitation) (20,21).
The primary outcome was clinical embolic events involv-
ing the brain or other organs. Clinical evidence of stroke
was defined as a new neurologic deficit persisting for longer
than 24 h and an absence of intracerebral hemorrhage or
tumor on computed tomography. Because it is difficult to
definitively differentiate an embolic stroke from a nonem-
bolic stroke, all new strokes were considered a primary
outcome event for the purpose of the study. Vascular
phenomena, such as cutaneous microinfarctions, were not
included. Similarly, metastatic abscesses were also not con-
sidered as embolic events. The cerebral emboli on computed
tomography were defined as an infarction within the terri-
tory of a cerebral artery or multiple areas of infarction.
Another important outcome was cerebral hemorrhage. A
cerebral hemorrhage was diagnosed as a well-defined area of
high density with irregular boundaries.
Secondary outcome events included subclinical strokes
detected by cerebral computed tomography, death, major or
minor bleeding, valve surgery, and echocardiographic pro-
gression of valvular involvement. Major bleeding was de-
fined as: 1) intracranial bleeding; 2) overt bleeding resulting
in a decrease in hemoglobin 20 g/l or requiring blood
transfusion; and 3) bleeding into a confined space, which
can cause severe morbidity, such as pericardial hematoma or
paraspinal hematoma. A minor hemorrhage was defined as
all other overt bleeding episodes with a drop in hemoglobin
20 g/l. Bruising or oozing at the intravenous sites alone
would not be qualified as minor bleeding.
Sample size. The clinical embolic rate in the placebo group
was estimated to be 26%, based on our own pilot data and
other published reports (4–7,22). We estimated that aspirin
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would reduce the embolic rate by 8.58% (33% relative
reduction). To observe this difference, 184 participants had
to be randomized to each intervention group (type I error
rate of 5% [two-sided]; type II error rate of 20%). The trial
was designed and statistically powered to incorporate an
interim analysis performed by a Data Safety and Monitoring
Committee. In view of the low enrollment, an interim
analysis was not performed. The Data Safety and Monitor-
ing Committee was informed of all major adverse events,
such as cerebral hemorrhage.
Data analysis. An intention-to-treat approach was used to
analyze the data. Odds ratios (ORs) and measures of
precision (i.e., 95% confidence intervals [CIs]) were com-
puted on all primary and secondary outcome data (23).
Statistically significant intervention differences were consid-
ered at the 5% level (two-sided). Descriptive statistics were
generated for each intervention group. Differences in clin-
ical embolic event rates and cerebral hemorrhage between
the two intervention groups were assessed using contin-
gency table analyses. A preliminary examination of each
valve stratum, using the Mantel-Haenzel approach, revealed
no statistical differences in any outcome (all p values 0.5).
Secondary outcomes were evaluated in a similar manner,
using the chi-square or Student t test, depending on the
scale of measurement.
RESULTS
During the four-year study period, 115 patients with left-
sided endocarditis were randomized into the trial, compris-
ing 91 patients with native valve endocarditis and 22
patients with prosthetic valve endocarditis. In the 398
patients who did not meet the inclusion criteria, the reasons
were the need for cardiac surgery in the next seven days (n
 105), already on aspirin (n  90), right-sided endocar-
ditis (n  66), recent or acute stroke (n  65), perivalvular
abscess (n  38), and bleeding diathesis (n  34). Sixty
patients were randomized to receive aspirin and 55 patients
were randomized to placebo. Their clinical characteristics are
shown in Table 1, and the results of laboratory investigations
are shown in Table 2. Staphylococcus aureus and Streptococcus
viridans were common pathogens in both groups.
Outcome events. The overall embolic rate was 29% for the
entire group, including both randomized and nonrandom-
ized patients. The primary and secondary outcome events
between the two groups are shown in Table 3. There were
no differences between the two groups in the primary
outcomes of clinical embolic events or intracranial hemor-
rhage. Clinical embolic events occurred in 17 patients
(28.3%) on aspirin and 11 patients (20.0%) on placebo (OR
1.62, 95% CI 0.68 to 3.86, p  0.29). The central nervous
system was the site of embolization in eight patients on
aspirin and three patients on placebo. Overall bleeding,
including major or minor episodes, was higher (p  0.075)
in the group that received aspirin (n  17 [28.8%] vs. 8
[14.5%]; OR 1.92, 95% CI 0.76 to 4.86). Similar numbers
of patients in both groups underwent valve surgery. The
duration of fever on treatment was also similar between the
two groups. Similar findings were obtained when only
patients with native valve endocarditis were analyzed.
Cerebral computed tomograms were obtained in 84
patients at the end of therapy (43 in the aspirin group and
41 in the placebo group). There were no differences in
intracerebral abnormalities between the two groups (Table 4).
Effect on vegetation. The effects of antibiotic treatment on
the evolution of vegetation and valvular regurgitation were
evaluated by serial transesophageal echocardiography at
baseline and after four weeks of treatment in 46 patients (23
patients each on aspirin or placebo) (Table 5). The vegeta-
tion diminished in size in both groups of patients and to
similar degrees. Both absolute changes and percent changes
were no different between the groups. The severity of
valvular insufficiency was also similar between the two
groups at both time points.






Age (yrs) 54.9  14.7 56.9  16.7
Women 16 (26.7) 15 (27.3)
Prosthetic valve 10 (16.7) 14 (25.5)
Pre-existing native valve disease 38 (63.3) 34 (61.8)
Anticoagulation therapy 13 (21.7) 13 (23.6)
Previous endocarditis* 4 (20) 6 (26.1)
Dental procedure within 12 weeks 12 (20) 10 (18.2)
Intravenous drug use 5 (8.3) 9 (16.4)
Symptom duration (days) 34.5  48.3 33.5  54.3
*Based on 20 patients in the aspirin group and 23 patients in the placebo group. Data
are presented as the mean value  SD or number (%) of patients.






Hemoglobin (g/l) 116.5  22.0* 113.4  20.5†
Platelets (109/l) 234.3  132.0 235.1  145.1†
Positive blood culture 57 (95) 49 (89.1)
Staphylococcus aureus 14 (25) 16 (32.7)
Streptococcus viridans 19 (33.9) 18 (36.7)
Other streptococci 7 (12.5) 8 (16.3)
Enterococci 9 (16.1) 2 (4.1)
Coagulase-negative staphylococci 2 (3.6) 2 (4.1)
Others 5 (8.9) 3 (6.1)
Vegetation by transthoracic
echocardiography
Aortic valve 19 (31.7) 13 (23.6)
Mitral valve 10 (16.7) 13 (23.6)
Vegetation by transesophageal
echocardiography
Aortic valve‡ 22 (41.5) 23 (46)
Mitral valve§ 30 (57.7) 21 (42)
*Data available for 59 patients. †Data available for 54 patients. ‡Based on 53 patients
in the aspirin group and 50 patients in the placebo group. §Based on 52 patients in
the aspirin group and 50 patients in the placebo group. Data are presented as the mean
value  SD or number (%) of patients.
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DISCUSSION
In IE, embolism is a major complication that is one of the
main causes of death (4–7). Despite advances in medical
and surgical treatments, the incidence of embolism has
remained high at about 30% (4–7,24,25). Although pro-
phylactic surgery has been suggested to prevent embolism,
this application has not been prospectively tested and
generally not widely accepted.
Although circulating factors, such as antiphospholipid
antibodies and coagulation factors, may play a role (26,27),
vegetation detected by echocardiography remains the most
consistent risk factor for the development of embolic events
(4). Vegetation is made up of an aggregation of fibrin and
platelets (12–14). The effects of antiplatelet agents such as
sulfinpyrazone, ticlopidine, and aspirin in experimental
endocarditis are generally favorable (12–15,28 –30).
Whether some of the agents such as aspirin possess an
antibacterial effect in addition to their antiplatelet actions
remains controversial (29–31). Taha et al. (16) reported that
aspirin prevented vegetation growth and reduced the risk of
cerebral emboli in a small study of nine patients. The
findings of these studies were the basis for undertaking the
present study, which is the first randomized, controlled trial
to assess the effect of aspirin in patients with endocarditis. A
recent study by Kupferwasser et al. (14) showed that aspirin
reduced vegetation size and renal embolic lesions without an
increase in major bleeding in a rabbit model of staphylo-
coccal endocarditis, further underscoring the need for a
prospective study in this regard. We excluded unstable
patients, including those with perivalvular abscess, because
they would have an increased likelihood of requiring surgical
intervention (11,12), and aspirin use may exacerbate peri-
operative bleeding.
The embolic rate in this trial is similar to the rates found
in other studies (4–7,24,25). No difference in embolic
events was observed between patients taking aspirin and
those on placebo. Similar proportions of patients in both
treatment groups had serial cerebral computed tomograms,
and again, no differences were found between the two
treatment groups in terms of intracerebral abnormalities.
We did not encounter clinical embolic events in other organ
systems, such as the kidneys or spleen, although routine
radiologic assessment to look for embolization in these
organs was not performed.
Furthermore, we were unable to demonstrate any signif-
icant effect of aspirin on the number and size of the
vegetations, although there was a significant reduction in
vegetation size after antibiotic treatment for four weeks in
both groups. There was also no salutary effect of aspirin on
valvular dysfunction.
Patients with endocarditis are prone to the development
of cerebral hemorrhage, which can have multiple mecha-
nisms, with the majority due to septic arteritis and hemor-
rhagic transformation of embolic infarction rather than
mycotic aneurysm (32). Anticoagulation treatment with
warfarin has been reported to increase the risk of cerebral
hemorrhage and is not associated with a reduction in
embolic events (32–35). Our findings showed that anti-
platelet treatment with aspirin also likely increased the risk
of major or minor bleeding. The effect of aspirin on the
frequency of cerebral hemorrhage alone could not be ade-
quately addressed because of the small number of events.
We included both native valve and prosthetic valve
endocarditis in this trial because patients with prosthetic
valve endocarditis have a high embolic rate, despite contin-





(n  41) p Value
Focal lesions 5 (11.6) 6 (14.6) 0.933
Multifocal lesions 5 (11.6) 4 (9.8) 0.931
Hemorrhage 7 (16.3) 2 (4.9) 0.182
Abscess 0 0
Total 17 (39.5) 12 (29.3) 0.451
Data are presented as the number (%) of patients.




(n  55) OR (95% CI) p Value
Embolism or intracranial hemorrhage 20 (33.9) 14 (25.5) 1.50 (0.67–3.38) 0.413
Embolism 17 (28.8) 11 (20) 1.62 (0.68–3.86) 0.287
Heart failure 23 (39.7)* 17 (30.9) 1.47 (0.68–3.20) 0.431
Renal dysfunction 13 (22) 16 (29.1) 0.69 (0.30–1.61) 0.400
Perivalvular abscess 3 (5.1) 2 (3.6) 1.42 (0.23–8.83) 1.000
Valve surgery 18 (30.5) 13 (23.6) 1.42 (0.62–3.26) 0.528
In-hospital death 4 (6.7)† 6 (10.9) 0.58 (0.16–2.19) 0.516
Duration of fever (days) 5.9  0.9‡ 5.3  1.0 — 0.689
Major bleeding
Intracranial 7 (11.9) 3 (5.5) 2.33 (0.57–9.52) 0.324
20 g/l drop in hemoglobin or into confined space 9 (15) 5 (10.9) 1.76 (0.55–5.63) 0.400
Minor bleeding 8 (13.6) 2 (3.6) 4.16 (0.84–20.52) 0.096
Major or minor bleeding 17 (28.8) 8 (14.5) 1.92 (0.76–4.86) 0.075
*Data available for 58 patients. †Data available for 60 patients. ‡Data available for 54 patients. Data are presented as the number
(%) of patients or mean value  SD.
CI  confidence interval; OR  odds ratio.
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uation of anticoagulation (18), and the risk of excessive
bleeding associated with the combined use of anticoagulants
and aspirin in patients with mechanical heart valves has
been reported to be quite modest (36,37). The increased risk
of bleeding with aspirin was observed in patients with native
and prosthetic valve endocarditis. The sample size does not
allow an assessment of the differential effects of aspirin in
native versus prosthetic valve endocarditis.
This study only assessed the effect of aspirin during the
acute phase of endocarditis, and the long-term effect on
outcomes was not determined. We believe this is appropri-
ate, as embolic events occurred almost exclusively early in
the course of the disease (5). The average duration from
symptom onset to presentation was about one month, and
this may explain why most of the embolic events occurred
early during hospitalization (5). Whether the use of aspirin
shortly after symptom onset may have different effects
remains to be determined. It is plausible that aspirin may
have a salutary effect if used earlier in the course of the
disease. The manifestations of endocarditis are protean, and
prompt diagnosis is difficult. Most patients with endocar-
ditis are unlikely to be diagnosed and treated significantly
earlier than the patients in this trial.
It may be argued that an optimal dose of aspirin may not
have been used in this trial, but an optimal aspirin dose has
not been established for this disease or other conditions
(38). The trend for an increased risk of bleeding in our
patients taking aspirin suggests that a higher dose is not
advisable. A lower dose may reduce the risk of bleeding, but
it is doubtful that it will have a beneficial effect on embolic
events, because a lower dose would be less effective in
reducing platelet fibrin aggregation (14).
Study limitations. Our study reached 31% (n  115) of its
target sample size (n  369). It is possible that our results
reflect a type II error (i.e., having insufficient statistical
power to observe the hypothesized 8.58% aspirin benefit of
reducing embolic events) (39). However, our results indicate
that the frequency of embolic events, similar to the size we
thought to be clinically meaningful, is in the opposite
direction than anticipated. As such, we believe that it is very
unlikely that a daily intake of 325 mg aspirin will be more
effective than placebo in preventing embolism in patients
with IE. These estimations also suggest that the embolic
rates could be similar in both intervention groups. The lack
of a salutary effect of aspirin in these patients was collabo-
rated by the observations regarding the cerebral abnormal-
ities on computed tomograms and vegetation resolution on
serial transesophageal echocardiograms, which were similar
between the treatment groups.
Conclusions. In stable patients with endocarditis without
perivalvular abscess, the addition of aspirin (325 mg) to
antibiotic treatment does not appear to reduce the embolic
risk, but may increase the risk of bleeding. Aspirin also does
not reduce the development of cerebral lesions nor enhance
vegetation resolution. Thus, aspirin is not indicated in the
early management of patients with IE.
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APPENDIX
The following centers and local principal investigators
participated in the Multicenter Aspirin Study in Infective
Endocarditis: C. Thompson, St. Paul’s Hospital, Vancou-
ver, British Columbia, Canada; J. Jue, Vancouver General
Hospital, Vancouver; D. Taylor, University of Edmonton
Hospital, Edmonton, Alberta; T. Prieur, Holy Cross and
Calgary General Hospitals, Calgary, Alberta; B. Cujec,
Royal University Hospital, Saskatoon, Saskatchewan; A.
Aboguddah, Regina General Hospital, Regina, Saskatche-
wan; J. Tam, Health Science Center, Winnipeg, Manitoba;
L. Melendez, Victoria Hospital, London, Ontario; C.
Tomlinson, Hamilton Hospitals, Hamilton, Ontario; S.
Siu, The Toronto Hospitals, Toronto, Ontario; C. Joyner,
Sunnybrook Health Science Center, Toronto; T. Robinson,
St. Michael’s Hospital, Toronto; A. Sanfilippo, Hotel Dieu
and Kingston General Hospital, Kingston; K. Chan, F.
Auclair, R. Saginur, P. Jessamine, Ottawa Hospital, Civic
Campus (Coordinating Center), Ottawa, Ontario; M.
Turek, Ottawa Hospital, General Campus, Ottawa, On-
tario; G. Honos, Jewish General Hospital, Montreal, Que-
bec; L. Mercier, Montreal Heart Institute, Montreal, Que-
bec; J. Dumesnil, Laval Hospital, Laval, Quebec; and D.
Hess, University of Missouri Medical Center, Columbia,
Missouri.
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